Jean Bourhis

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
    Jean Bourhis
    Radiation Oncology Department, Institut Gustave Roussy, Villejuif, France
    Lancet 368:843-54. 2006
  2. doi Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial
    Jean Bourhis
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 13:145-53. 2012
  3. ncbi Meta-analyses in head and neck squamous cell carcinoma. What is the role of chemotherapy?
    J Bourhis
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Hematol Oncol Clin North Am 13:769-75, vii. 1999
  4. ncbi New approaches to enhance chemotherapy in SCCHN
    J Bourhis
    Institut Gustave Roussy, Villejuif 94805, France
    Ann Oncol 16:vi20-vi24. 2005
  5. ncbi Randomized trials of amifostine and radiotherapy: effect on survival?
    J Bourhis
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, Cedex France
    Semin Oncol 31:62-6. 2004
  6. doi Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial
    Jean Bourhis
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Radiother Oncol 100:56-61. 2011
  7. ncbi [Larynx preservation: nonsurgical approaches]
    J Bourhis
    Departement de Radiotherapie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Cancer Radiother 8:S24-8. 2004
  8. ncbi Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Jean Bourhis
    Institut Gustave Roussy, Radiotherapie, Villejuif, France
    J Clin Oncol 24:2866-72. 2006
  9. ncbi Redefining 'state of the art' in head and neck cancer
    J Bourhis
    Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France
    Ann Oncol 16:vi5-vi6. 2005
  10. ncbi [Biomodulation and radiotherapy]
    J Bourhis
    Département de radiothérapie et unité propre de l enseignement supérieur UPRES EA 27 10, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Cancer Radiother 4:128s-133s. 2000

Detail Information

Publications136 found, 100 shown here

  1. ncbi Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
    Jean Bourhis
    Radiation Oncology Department, Institut Gustave Roussy, Villejuif, France
    Lancet 368:843-54. 2006
    ..The aim of this meta-analysis was to assess whether this type of radiotherapy could improve survival...
  2. doi Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial
    Jean Bourhis
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 13:145-53. 2012
    ..We aimed to assess the efficacy and safety of a combination of these approaches...
  3. ncbi Meta-analyses in head and neck squamous cell carcinoma. What is the role of chemotherapy?
    J Bourhis
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Hematol Oncol Clin North Am 13:769-75, vii. 1999
    ....
  4. ncbi New approaches to enhance chemotherapy in SCCHN
    J Bourhis
    Institut Gustave Roussy, Villejuif 94805, France
    Ann Oncol 16:vi20-vi24. 2005
    ..Promising activity has also been observed with a number of other EGFR inhibitors, both MAbs and tyrosine kinase inhibitors...
  5. ncbi Randomized trials of amifostine and radiotherapy: effect on survival?
    J Bourhis
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, Cedex France
    Semin Oncol 31:62-6. 2004
    ..It will be also possible to study the effect(s) of amifostine in different tumor types...
  6. doi Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial
    Jean Bourhis
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Radiother Oncol 100:56-61. 2011
    ..The objective was to evaluate the efficacy of a strong increase of the dose-intensity of concomitant radio-chemotherapy (RT-CT) in patients with far advanced non metastatic HNSCC...
  7. ncbi [Larynx preservation: nonsurgical approaches]
    J Bourhis
    Departement de Radiotherapie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Cancer Radiother 8:S24-8. 2004
    ..Finally, larynx preservation is generally not proposed in patients with deeply infiltrating tumors and or tumor invading the cartilage or soft tissue in the neck (T4)...
  8. ncbi Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Jean Bourhis
    Institut Gustave Roussy, Radiotherapie, Villejuif, France
    J Clin Oncol 24:2866-72. 2006
    ..This was an open, randomized, multicenter, phase I/II study to investigate the safety and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN)...
  9. ncbi Redefining 'state of the art' in head and neck cancer
    J Bourhis
    Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France
    Ann Oncol 16:vi5-vi6. 2005
  10. ncbi [Biomodulation and radiotherapy]
    J Bourhis
    Département de radiothérapie et unité propre de l enseignement supérieur UPRES EA 27 10, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Cancer Radiother 4:128s-133s. 2000
    ..In addition, other promising ways to modulate radiation-induced response concern extracellular or tissue factors such as hypoxia and angiogenesis...
  11. ncbi Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial
    Jean Bourhis
    Institut Gustave Roussy, Radiation Oncology, Head and Neck Statistics Department, Villejuif, France
    J Clin Oncol 24:2873-8. 2006
    ....
  12. ncbi Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC)
    J Bourhis
    Department of Radiation Oncology, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Semin Oncol 31:822-6. 2004
    ..The two regimens are currently being tested in an ongoing randomized study and also being compared to moderately accelerated RT and concomitant CT...
  13. ncbi Altered fractionated radiotherapy in the management of head and neck carcinomas: advantages and limitations
    Jean Bourhis
    Institut Gustave Roussy, Radiation Oncology and Statistic Departments, Villejuif, France
    Curr Opin Oncol 16:215-9. 2004
    ..This article provides an overview of randomized studies of altered fractionated radiotherapy (RT) in Head and Neck squamous cell carcinoma...
  14. ncbi A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma
    J Bourhis
    Radiation Oncology, Head and Neck Surgery, Villejuif, France
    Int J Radiat Oncol Biol Phys 46:1105-8. 2000
    ..The aim of this study was to assess whether amifostine could minimize acute mucositis induced by a very accelerated irradiation regimen in patients with advanced head and neck squamous cell carcinoma (HNSCC)...
  15. ncbi Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo
    Laurence Maggiorella
    Laboratoire Radiosensibilité des Tumeurs et des Tissus Sains UPRES EA 27 10, 94805 Villejuif, Cedex, France
    Cancer Res 63:2513-7. 2003
    ..In conclusion, we found a novel effect on DNA repair of the CDK inhibitor roscovitine, which acts as a radiosensitizer in vitro and in vivo in breast cancer cells lacking a functional p53...
  16. ncbi The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe
    Yungan Tao
    UPRES EA27 10 Laboratoire Radiosensibilité des Tumeurs et Tissus Sains, Villejuif, France
    Cell Cycle 8:3172-81. 2009
    ..Altogether, these data support the contention that AZD1152 mediates radiosensitization in vivo by enhancing mitotic catastrophe, which can be used as a biomarker of treatment efficacy...
  17. ncbi Successful mitigation of delayed intestinal radiation injury using pravastatin is not associated with acute injury improvement or tumor protection
    Valerie Haydont
    UPRES EA 27 10, Radiosensibilite des tumeurs et tissus sains, Institut de Radioprotection et de Sûreté Nucléaire Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 68:1471-82. 2007
    ....
  18. ncbi Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats
    Valerie Haydont
    UPRES EA 27 10 Radiosensibilité des tumeurs et tissus sains, Institut de Radioprotection et de Sûreté Nucléaire Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 13:5331-40. 2007
    ..Among these new targets, we identified the Rho/ROCK pathway and thought to investigate whether pravastatin treatment inhibits Rho pathway activation and elicits an antifibrotic action...
  19. ncbi Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model
    Laurence Maggiorella
    Laboratoire UPRES EA No 27 10 Radiosensibilité des tumeurs et tissus sains, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Anticancer Res 25:4357-62. 2005
    ..These data suggested that Ritonavir could clinically improve the tumor response to radiation therapy, especially in head and neck carcinoma...
  20. doi Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection
    Monica Mangoni
    Laboratoire UPRES EA 2710, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 74:1242-50. 2009
    ....
  21. doi Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data
    Stefan Michiels
    Department of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 10:341-50. 2009
    ..This would allow a reduction in the duration and cost of the development of new treatments...
  22. ncbi Global gene expression profiles reveal an increase in mRNA levels of collagens, MMPs, and TIMPs in late radiation enteritis
    Carine Strup-Perrot
    Laboratoire UPRES EA 27 10 Radiosensibilité des Tumeurs et Tissus Sains, Institut Gustave Roussy Institut de Radioprotection et de Sureté Nucléaire, 94805 Villejuif, France
    Am J Physiol Gastrointest Liver Physiol 287:G875-85. 2004
    ..This demonstrates that established fibrotic tissue is not scarred fixed tissue but is subjected to a dynamic remodeling process...
  23. ncbi Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion
    Alexandre Kaliski
    Unité Propre de Recherche de l Enseignement Supérieur Equipe d Accueil 27 10, Villejuif, France
    Mol Cancer Ther 4:1717-28. 2005
    ..This model could provide in vivo evidence of the antitumor efficacy of combining a MMP inhibitor with ionizing radiation to target radiation-induced invasion and angiogenesis...
  24. doi Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data
    Jean Bourhis
    Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France
    J Clin Oncol 29:2590-7. 2011
    ..The aim of this meta-analysis was to evaluate the impact of amifostine on overall survival (OS) and progression-free survival (PFS) in patients treated with radiotherapy or chemoradiotherapy...
  25. ncbi Cidofovir administered with radiation displays an antiangiogenic effect mediated by E6 inhibition and subsequent TP53-dependent VEGF repression in HPV18+ cell lines
    Abdessamad Amine
    Laboratoire UPRES EA 27 10 Radiosensibilité des Tumeurs et Tissus Sains, Institut Gustave Roussy, Villejuif, France
    Radiat Res 166:600-10. 2006
    ..This study showed that the combination of cidofovir with ionizing radiation has an antiangiogenic effect associated with VEGF inhibition subsequent to E6 inhibition and TP53 restoration...
  26. doi Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group
    Pierre Blanchard
    Institut Gustave Roussy, Villejuif Cedex, France
    J Clin Oncol 31:2854-60. 2013
    ..007), and 0.63 (95% CI, 0.45 to 0.89; P = .009) respectively. CONCLUSION This IPD meta-analysis shows the superiority of Tax-PF over PF as induction chemotherapy. Its precise role in the management of LAHNC remains to be determined. ..
  27. ncbi Treatment of the N0 neck during salvage surgery after radiotherapy of head and neck squamous cell carcinoma
    Stephane Temam
    Department of Otorhinolaryngology Head and Neck Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Head Neck 27:653-8. 2005
    ..The aim of this study was to determine the rate of occult neck node metastasis and the surgical morbidity of patients after salvage surgery for local relapse after definitive radiotherapy...
  28. doi Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma
    Francois Janot
    Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif, France
    J Clin Oncol 26:5518-23. 2008
    ..The Groupe d'Etude des Tumeurs de la Tête et du Cou and Groupe d'Oncologie Radiothérapie Tête Et Cou groups performed a randomized study to assess its efficacy...
  29. doi Current concepts of management in radiotherapy for head and neck squamous-cell cancer
    Renaud Mazeron
    Department of Radiotherapy, Institute Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France
    Oral Oncol 45:402-8. 2009
    ..Finally management of treatment related acute or late toxicity remains an important issue and in the last decade major achievements have been obtained in this field especially using intensity modulated radiotherapy (IMRT)...
  30. doi Salvage surgery after concomitant chemoradiation in head and neck squamous cell carcinomas - stratification for postsalvage survival
    Hiang Khoon Tan
    Department of Head and Neck Surgery, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Head Neck 32:139-47. 2010
    ..Salvage surgery after concomitant chemoradiation therapy (CCRT) for patients with head and neck squamous cell carcinomas (HNSCC) is challenging because of its associated morbidity/mortality and the poor prognoses of these patients...
  31. pmc Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells
    Abdessamad Amine
    Laboratoire UPRES EA 27 10 Radiosensibilité des Tumeurs et Tissus Sains, Institut Gustave Roussy Institut de Radioprotection et de Sureté Nucléaire, Villejuif, France
    PLoS ONE 4:e5018. 2009
    ..These data suggest a novel and highly translatable therapeutic approach to cervix cancer, by inhibition of adhesion and invasion of circulating HPV-positive tumor cells, using Cidofovir and/or ROCK inhibition...
  32. ncbi Individual patients' data meta-analyses in head and neck cancer
    Jean Bourhis
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Curr Opin Oncol 19:188-94. 2007
    ..The database included nearly 120 randomized trials, and about 25,000 patients, with a median follow-up of 6 years...
  33. pmc Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02
    Yungan Tao
    Institute Gustave Roussy, Villejuif, France
    Radiat Oncol 8:40. 2013
    ..This study sought to determine the maximum tolerated dose (MTD) of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma (HNSCC)...
  34. ncbi [Concomitant chemoradiation in patients with cervix cancer]
    Christine Haie-Meder
    Service de curiethérapie, Departement de Radiotherapie, Institut Gustave Roussy, rue Camille Desmoulins, 94800 Villejuif
    Bull Cancer 92:1032-8. 2005
    ..Future randomised trials should also aim to establish optimal chemotherapy regimens for combination with radiotherapy...
  35. ncbi Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma
    Stephane Temam
    Department of Otorhinolaryngology Head and Neck Surgery, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Int J Radiat Oncol Biol Phys 62:1078-83. 2005
    ..To assess the efficacy and toxicity of salvage surgery for local or cervical nodal recurrence after accelerated radiotherapy for locally advanced head-and-neck squamous cell carcinoma (HNSCC)...
  36. doi Interfractional set-up errors evaluation by daily electronic portal imaging of IMRT in head and neck cancer patients
    Berrin Pehlivan
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Acta Oncol 48:440-5. 2009
    ..We aimed to evaluate whether a daily PI is worthwhile and we derived the Planning Target Volume (PTV) margins from the estimation of systematic and random errors...
  37. ncbi Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response
    Yohann Loriot
    UPRES 27 10, Institut Gustave Roussy, Villejuif, France
    Anticancer Res 30:3869-78. 2010
    ..The present study evaluated the efficacy of combining BCL-2 ODN and radiation in small-cell lung cancers (SCLC) cell lines...
  38. doi Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer
    Pierre Blanchard
    Department of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, France
    J Clin Epidemiol 64:985-92. 2011
    ..Mixed treatment comparison (MTC) meta-analysis allows one to perform simultaneous inference regarding all treatments and select the best among them...
  39. ncbi Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints
    Yungan Tao
    UPRES EA27 10 Laboratoire Radiosensibilité des Tumeurs et Tissus Sains, University Paris Sud XI Kremlin Bicêtre and Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif, France
    Cell Cycle 8:1196-205. 2009
    ..Altogether these results suggest that Chir-124-mediated radiosensitization is profoundly influenced by the p53 and cell cycle checkpoint system...
  40. doi Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients
    Jean Pierre Pignon
    Department of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, France
    Radiother Oncol 92:4-14. 2009
    ..However the heterogeneity of the results limited the conclusions and prompted us to confirm the results on a more complete database by adding the randomised trials conducted between 1994 and 2000...
  41. ncbi Gene expression profile in human late radiation enteritis obtained by high-density cDNA array hybridization
    Marie Catherine Vozenin-Brotons
    Laboratoire UPRES EA 27 10 Radiosensibilité des Tumeurs et Tissus Sains, Institut Gustave Roussy Institut de Radioprotection et de Sureté Nucléaire, Villejuif, France
    Radiat Res 161:299-311. 2004
    ..e. the mucosa, the mesenchyme, and blood vessels. Functional studies will be necessary to validate the present results...
  42. ncbi BCR-ABL down-regulates the DNA repair protein DNA-PKcs
    E Deutsch
    , Institut Gustave Roussy, Villejuif, France
    Blood 97:2084-90. 2001
    ..The down-regulation of DNA-PKcs was reversible in CD34(+) CML cells suggesting that this approach might offer a novel and powerful therapeutic strategy in this disease, especially to delay the blast crisis. (Blood. 2001;97:2084-2090)..
  43. ncbi Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update
    Jean Pierre Pignon
    Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 69:S112-4. 2007
  44. doi Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents
    Nicolas Magne
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Cancer Metastasis Rev 27:737-50. 2008
    ....
  45. doi Oral cavity squamous cell carcinoma in 260 patients aged 80years or more
    Cecile Ortholan
    Department of Radiotherapy, Centre Antoine Lacassagne, Nice, France
    Radiother Oncol 93:516-23. 2009
    ..We report the experience of two French cancer centers in the treatment of oral cavity squamous cell carcinoma (SCC) in patients aged 80 years...
  46. doi A phase I trial combining oral cisplatin (CP Ethypharm) with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma
    Yungan Tao
    Institute Gustave Roussy, Villejuif, France
    Radiother Oncol 98:42-7. 2011
    ..To determine the maximum tolerated dose (MTD) of oral cisplatin (CP Ethypharm®) in combination with radiotherapy in head and neck squamous cell carcinoma (HNSCC) and the recommended dose for phase II trials...
  47. ncbi Comparison of dose contribution to normal pelvic tissues among conventional, conformal and intensity-modulated radiotherapy techniques in prostate cancer
    Yungan Tao
    Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Acta Oncol 47:442-50. 2008
    ..A long-term follow-up will be needed to evaluate potential late treatment complications related to the use of IMRT and the low or moderate irradiation dose level obtained in the pelvis and in the whole body...
  48. doi Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
    Jean Bourhis
    Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France
    Eur J Cancer 46:1979-89. 2010
    ..Preliminary evidence suggests that cetuximab could be incorporated into induction management strategies. Taken together, these data support an important role for cetuximab in the treatment paradigm for locoregionally advanced SCCHN...
  49. ncbi Glucagon-like peptide-2 improves both acute and late experimental radiation enteritis in the rat
    Sandra Torres
    Radiosensibilité des Tumeurs et des Tissus Sains, UPRES EA 2710, Institut de Radioprotection et de Sûreté Nucléaire Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 69:1563-71. 2007
    ..The therapeutic potential of acute administration of glucagon-like peptide-2 (GLP-2) against acute and chronic intestinal injury was investigated in this study...
  50. doi The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials
    Nicolas Magne
    Department of Radiotherapy, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94 805 Villejuif, France
    Eur J Cancer 44:2133-43. 2008
    ..Here we report all the different published clinical trials focusing on efficacy and toxicity in order to clarify and to summarise the present state-of-the-art of this particularly promising combination in solid tumour management...
  51. ncbi Hyperfractionated or accelerated radiotherapy for head and neck cancer
    Bertrand Baujat
    Head and Neck Surgery, Hopital Foch, 40 rue Worth, Suresnes, France, 92150
    Cochrane Database Syst Rev 12:CD002026. 2010
    ..Several trials have studied the role of altered fractionation radiotherapy in head and neck squamous cell carcinoma, but the effect of such treatment on survival is not clear...
  52. ncbi Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells
    Bixiu Wen
    UPRES EA No 27 10, Radiosensibilité des tumeurs et des tissues sains, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Urol 170:2036-9. 2003
    ..We examined the potential therapeutic effect of NS398, a selective cyclooxygenase-2 (COX-2) inhibitor, combined with irradiation on human prostate adenocarcinoma DU145 cells...
  53. doi Definitive radiotherapy for squamous cell carcinoma of the pyriform sinus
    Pierre Blanchard
    Institut Gustave Roussy, Villejuif, France
    Radiother Oncol 105:232-7. 2012
    ..To report the long-term results after definitive radiotherapy (RT) for pyriform sinus squamous cell carcinoma (SCC)...
  54. doi Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy
    Céline Clémenson
    INSERM U1030, Radiothérapie moléculaire, Institut Gustave Roussy, Universite Paris XI, Villejuif, France
    Invest New Drugs 30:2173-86. 2012
    ..This provides a good rationale to further assess EHT 6706 in combination protocols and confirm these effects in vivo...
  55. doi Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination
    Pierre Mordant
    UPRES 2710, Universite Paris XI, Institut Gustave Roussy, Villejuif, 94805 France
    Mol Cancer Ther 9:358-68. 2010
    ..The combination of RAF and mTOR inhibitors is effective for enhancing antitumoral effects in cells with deregulation of both RAS-RAF and PI3K, possibly through the cross-inhibition of 4E binding protein 1 and S6 protein...
  56. ncbi Quantified relationship between cellular radiosensitivity, DNA repair defects and chromatin relaxation: a study of 19 human tumour cell lines from different origin
    Nicole Chavaudra
    UPRES EA 2710, Institut Gustave Roussy, 94805 Villejuif, France
    Radiother Oncol 73:373-82. 2004
    ..Nineteen human tumour cell lines, representing a large spectrum of radiation responses and tissues, were examined...
  57. ncbi Induction of CTGF by TGF-beta1 in normal and radiation enteritis human smooth muscle cells: Smad/Rho balance and therapeutic perspectives
    Valerie Haydont
    UPRES EA 27 10 Radiosensibilité des tumeurs et tissus sains, Institut Gustave Roussy Institut de Radioprotection et de Sureté Nucléaire, Villejuif, France
    Radiother Oncol 76:219-25. 2005
    ....
  58. ncbi [Locoregional recurrences of HNSCC: place of re-irradiations]
    Jean Bourhis
    Radiothérapie et chirurgie cervico faciale, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex
    Bull Cancer 91:871-3. 2004
    ..Indeed, the feasibility of this approach has been shown, and may be associated with a curative potential in a relatively low proportion of these relapses...
  59. pmc Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells
    B Wen
    , Institut Gustave Roussy, , France
    Br J Cancer 85:2017-21. 2001
    ..These results suggest that Tyrphostin AG 1024 could be used as a potential therapeutic agent in combination with irradiation...
  60. ncbi Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma
    R De Crevoisier
    , Institut Gustave-Roussy, Villejuif, France
    Cancer 91:2071-6. 2001
    ..These results prompted the authors to initiate a multicentric randomized trial that is ongoing (GETTEC-GORTEC 99-01) to evaluate the benefit of adjuvant radiochemotherapy in these types of patients...
  61. doi Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome
    Gabriel G Malouf
    Department of Radiotherapy, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Eur J Cancer 49:1324-34. 2013
    ..Esthesioneuroblastomas, also called olfactory neuroblastomas (ENB) represent a rare sinonasal neurectodermal tumour which prognostic factors are unsteadily described...
  62. doi Early side effects of three-dimensional conformal external beam accelerated partial breast irradiation to a total dose of 40 Gy in one week (a phase II trial)
    Céline Bourgier
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 81:1228-35. 2011
    ..Nonetheless, the optimal radiation dose is not yet known. Here, we report feasibility and early toxicities of APBI delivering 40 Gy over 5 days, in a phase II trial...
  63. ncbi Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy
    Pierre Graff
    Department of Radiation Oncology, Alexis Vautrin Center, Vandoeuvre les Nancy, France
    Int J Radiat Oncol Biol Phys 67:1309-17. 2007
    ..To assess the benefit of intensity-modulated radiotherapy (IMRT) compared with conventional RT for the quality of life (QOL) of head and neck cancer survivors...
  64. ncbi Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers
    Radhia M'kacher
    Laboratoire de la Radiosensibilité des Tumeurs et des Tissus Sains, UPRES EA 27 10, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 68:465-71. 2007
    ..This study was premised on the finding that telomere dysfunction and DNA repair pathways were related to many pathologic conditions...
  65. ncbi Advances in radiotherapy of head and neck cancers
    Yungan Tao
    Department of Radiotherapy, Institute Gustave Roussy, Villejuif, France
    Curr Opin Oncol 22:194-9. 2010
    ..Radiation therapy plays a key role in the management of head and neck cancers (HNCs). We reviewed the recent advances in radiotherapy of HNCs and the role of imaging in treatment planning...
  66. ncbi Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma
    Jean Bourhis
    Institut Gustave Roussy, Villejuif Cedex, France
    Semin Oncol 29:61-2. 2002
    ..In conclusion, the experience obtained to date in HNSCC patients treated with radiotherapy supports the selective cytoprotective activity of amifostine to minimize radiation effects while apparently not diminishing tumor control...
  67. doi [Radiotherapy and targeted therapies in head and neck carcinomas and NSCLC]
    A Bruna
    Departement de Radiotherapie, Institut Gustave Roussy, 94800 Villejuif, France
    Bull Cancer 96:65-8. 2009
    ..Particularly, their addition to the reference treatments that are chemo-radiotherapy is studied. The first clinical results will be detailed, as well as their biological explanation...
  68. ncbi Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma
    R M'kacher
    Department of Medicine, UPRES EA 27 10, Villejuif, France
    Oncogene 22:7905-12. 2003
    ..These findings could clinically be exploited to increase the dismal response rates of MCL patients to the current chemotherapy regimens...
  69. ncbi End points for new agents in induction chemotherapy for locally advanced head and neck cancers
    C Monnerat
    Departments of Medicine, Head and Neck Surgery and Radiotherapy, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 13:995-1006. 2002
    ..Finally, we have examined the impact of new cytotoxic agents and present the promising results of new taxane-based combinations...
  70. doi Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial
    Etienne Bardet
    Department of Radiation Oncology, Centre Régional de Lutte Contre le Cancer Nantes Atlantique René Gauducheau, Nantes, France
    J Clin Oncol 29:127-33. 2011
    ..To compare compliance with and efficacy of intravenous (IV) and subcutaneous (SC) amifostine for the treatment of patients undergoing radiotherapy for head and neck cancer...
  71. ncbi Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck
    Jean Pierre Pignon
    Unit of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, France
    Anticancer Drugs 15:331-40. 2004
    ..We conclude that this improved survival might be due either to docetaxel's pharmacologic effect or to uncontrolled prognostic factors...
  72. doi Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer
    Markhaba Tukenova
    L Institut National de la Santé et de la Recherche Médicale, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Clin Oncol 28:1308-15. 2010
    ..The purpose of this study was to assess the role of treatment in long-term overall and cardiovascular mortality after childhood cancer...
  73. ncbi Environmental, genetic, and molecular features of prostate cancer
    Eric Deutsch
    Laboratoire UPRES EA 27 10, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 5:303-13. 2004
    ..This transition also signals a substantial worsening of prognosis. Here, we review the most important findings in prostate carcinogenesis and the molecular anomalies associated with the androgen-refractory stage...
  74. doi Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site
    Pierre Blanchard
    Biostatistics and Epidemiology Department, Institut Gustave Roussy, Villejuif, France
    Radiother Oncol 100:33-40. 2011
    ..The magnitude of the benefit according to tumour site is unknown as well as their potential interactions with patient or trial characteristics...
  75. doi Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts
    Cyrus Chargari
    Radiothérapie moléculaire, Universite Paris XI, Institut Gustave Roussy, Villejuif, France
    Cancer Lett 312:209-18. 2011
    ..Further investigations are warranted with regard to the molecular mechanisms underlying its actions and its dependency regarding p53 status...
  76. doi [Angiogenesis inhibitors and radiation therapy: concept and preliminary results]
    R Mazeron
    UPRES EA2710, laboratoire de radiosensibilité des tumeurs et des tissus sains, Institut Gustave Roussy, Villejuif, France
    Bull Cancer 96:299-310. 2009
    ..Hence, further studies need to be conducted to assess toxicities, doses and sequences of the combination. Numerous of phases I and II clinical trials are ongoing and answers are awaited...
  77. ncbi [Epidermal growth factor receptor (EGF) in head-and-neck cancers]
    J Bourhis
    Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 94:F189-91. 2007
    ..This suggests the potential interest of the combination between anti-EGFR drugs and cytotoxic agents, especially ionizing radiation with promising results obtained at the clinical level in locally advanced HNC...
  78. pmc Decreased DNA-PK activity in human cancer cells exhibiting hypersensitivity to low-dose irradiation
    S Vaganay-Juéry
    Unité Propre de l Enseignement Supérieur Radiosensibilité humaine, UPRES, Villejuif, France
    Br J Cancer 83:514-8. 2000
    ..This modulation of DNA-PK activity was a rapid phenomenon occurring within the 2 h following low-dose radiation exposure. These data strongly suggest the implication of the DNA-PK repair complex in the HRS phenomenon...
  79. ncbi [New strategies to interfere with radiation response: "biomodulation" of radiation therapy]
    E Deutsch
    Laboratoire de radiosensibilité des tumeurs et des tissus sains UPRES EA27 10, Departement de Radiotherapie, Institut Gustave Roussy, Villejuif, France
    Cancer Radiother 9:69-76. 2005
    ..3) Strategies which are not targeted against the tumor but the microenvironment, especially angiogenesis. This type of approaches seems to be applicable independently of tumor intrinsic biologic related factors...
  80. ncbi The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis
    L Maggiorella
    , , Institut Gustave Roussy, 94805 Villejuif Cedex, France
    Clin Cancer Res 7:2091-5. 2001
    ..In conclusion, the combination of IR and S16020 seems promising to enhance antitumor activity without increasing deleterious effect in normal tissues and to provide the basis for a new radio-chemotherapy combination...
  81. pmc n-3 polyunsaturated fatty acids decrease mucosal/epidermal reactions and enhance antitumour effect of ionising radiation with inhibition of tumour angiogenesis
    B Wen
    , Institut Gustave Roussy, 39, rue Camille Desmoulins, , France
    Br J Cancer 89:1102-7. 2003
    ..The magnitude of the differential effect suggests that n-3 PUFAs need to be further investigated in the clinic...
  82. ncbi Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients
    Bertrand Baujat
    Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 64:47-56. 2006
    ..To study the effect of adding chemotherapy to radiotherapy (RT) on overall survival and event-free survival for patients with nasopharyngeal carcinoma...
  83. ncbi Sensitivity to radiation and alkylating agent of peripheral lymphocytes and fibroblasts in a Hoyeraal-Hreidarsson syndrome patient
    Radhia M'kacher
    Service de Pediatrie, Centre Hospitalier Universitaire de Besancon, Bescancon, France
    Pediatr Hematol Oncol 20:651-6. 2003
    ..The data suggest that conditioning regimens including TBI should not be used when a bone marrow transplantation procedure is planned in these patients...
  84. doi Botulinum toxin for radiation-induced facial pain and trismus
    Dana M Hartl
    Department of Otolaryngology Head and Neck Surgery, Institut Gustave Roussy, Villejuif, France
    Otolaryngol Head Neck Surg 138:459-463. 2008
    ..To report the efficacy of botulinum toxin A for radiation-induced pain, trismus, and masticator spasm in head and neck cancer...
  85. ncbi [The cost of intensity modulated radiation therapy in head and neck cancers: results of the 2002 STIC study]
    M Julia Bonastre
    Institut Gustave Roussy, Direction des études économiques, 39 rue Camille Desmoulin, 94805 Villejuif
    Bull Cancer 93:1026-32. 2006
    ..For 70 % of the patients, reimbursement did not offset the cost of treatment. A financial support for hospitals implementing the technique is essential during the whole learning period...
  86. doi IMRT or conformal radiotherapy for adjuvant treatment of retroperitoneal sarcoma?
    Amaury Paumier
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Radiother Oncol 99:73-8. 2011
    ....
  87. ncbi Implications of learning effects for hospital costs of new health technologies: the case of intensity modulated radiation therapy
    Julia Bonastre
    Gustave Roussy Institute, Villejuif, France
    Int J Technol Assess Health Care 23:248-54. 2007
    ..The impact of learning effects on the variability of costs of new health technologies in a prospective payment system (PPS) through the case of intensity modulated radiation therapy (IMRT) was studied...
  88. ncbi Fibrogenic signals in patients with radiation enteritis are associated with increased connective tissue growth factor expression
    Marie Catherine Vozenin-Brotons
    Laboratoire UPRES EA 27 10 Radiosensibilité des Tumeurs et Tissus Sains, Institut Gustave Roussy Institut de Radioprotection et de Sureté Nucléaire, Villejuif, France
    Int J Radiat Oncol Biol Phys 56:561-72. 2003
    ..To investigate the expression of a new fibrogenic cytokine the connective tissue growth factor (CTGF) in intestinal radiation fibrosis and to characterize the mesenchymal cell subtypes involved in CTGF synthesis and collagen deposition...
  89. doi [Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy]
    E Bardet
    Departement de Radiotherapie, Centre Rene Gauducheau, Boulevard Jacques Monod, 44805 Nantes Saint Herblain, France
    Bull Cancer 96:1013-28. 2009
    ..The purpose of the present article was to evaluate indications, regimens, treatment modalities, and predictive factors of response to treatment in locally advanced squamous cell carcinoma of the head and neck (SCCHN)...
  90. doi [Accelerated partial breast irradiation: bifractionated 40Gy in one week. A French pilot phase II study]
    C Bourgier
    Département d Oncologie Radiothérapie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94800 Villejuif, France
    Cancer Radiother 14:718-26. 2010
    ..Here, we report the original dosimetric results of this technique...
  91. ncbi Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer
    J P Pignon
    Department of Biostatistics and Epidemiology, Institut Gustav Roussy, Villejuif, France
    Lancet 355:949-55. 2000
    ..We did three meta-analyses of the impact of survival on chemotherapy added to locoregional treatment...
  92. ncbi Radiotherapy in head and neck cancer in the elderly: a challenge
    J P Metges
    Department of Radiotherapy, Institut Gustave Roussy avenue Camille Desmoulins, 94805 Cedex, Villejuif, France
    Crit Rev Oncol Hematol 34:195-203. 2000
    ..However, specific trials concerning aged patients with head and neck cancer, quality of life and radiotherapy are warranted...
  93. doi Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas
    F Dhermain
    Department of Radiation Therapy, Institut Gustave Roussy, Villejuif, France
    J Neurooncol 97:81-8. 2010
    ..04 and 0.02, respectively. Different prognostic subgroups were identified, with 2-year PFS of 86%, 57%, and 19% for pts with no MVL, MVL without CE, and MVL with CE, respectively. MVL and CE seem to predict short-term outcome in ULGG pts...
  94. doi JC human polyomavirus is associated to chromosomal instability in peripheral blood lymphocytes of Hodgkin's lymphoma patients and poor clinical outcome
    R M'kacher
    Cell and Environment, 88bis rue des Pyrénées, Paris, France
    Ann Oncol 21:826-32. 2010
    ..We investigated JCV and Epstein-Barr virus (EBV) status in peripheral blood lymphocytes (PBL) from 74 Hodgkin's lymphoma (HL) and 91 B-cell non-Hodgkin's lymphoma (B-NHL) patients...
  95. ncbi Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin's lymphoma patients
    R M'kacher
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 57:321-6. 2003
    ..To study chromosomal abnormalities in 49 patients with Hodgkin's lymphoma (HL), before and after treatment and at several times during a 2-year period...
  96. ncbi Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152
    Y Tao
    Laboratory UPRES EA27 10 Radiosensitivity of tumors and normal tissues, Villejuif, France
    Oncogene 27:3244-55. 2008
    ..Altogether, these data indicate that AZD1152 can radiosensitize tumor cell lines in vitro and in vivo, the fact that these effects are exacerbated in p53-deficient cancer cells is of potential interest for further clinical development...
  97. ncbi [Role and perspectives of sentinel node biopsy in head and neck tumors]
    G Mamelle
    Département de Chirurgie Cervicofaciale, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Cancer Radiother 10:349-53. 2006
    ..To evaluate the accuracy of sentinel node biopsy for assessing the neck status for those patients with squamous cell carcinoma T1T2N0 of oral cavity...
  98. pmc Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation
    E Deutsch
    Laboratoire UPRES EA No 27 10, Radiosensibilite des tumeurs et tissus sains, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Br J Cancer 91:1735-41. 2004
    ..Therefore, these data suggest that Tyrphostin AG1024 could represent the basis of a novel therapy for STI571 refractory CML...
  99. ncbi [Individual patient data meta-analyses in head and neck carcinoma: what have we learnt?]
    J P Pignon
    Service de biostatistique et d épidémiologie, Département de Chirurgie Cervicofaciale, Departement de Radiotherapie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Cancer Radiother 9:31-6. 2005
    ..The results showed a small but significant improvement in favor of altered fractionated RT for overall survival and local control with an absolute benefit at five years of 3 and 6%, respectively...
  100. ncbi Chromosomal aberrations induced by chemotherapy and radiotherapy in lymphocytes from patients with breast carcinoma
    Jean Denis Légal
    UPRES EA29 10, Institut Gustave Roussy, Villejuif, France
    Int J Radiat Oncol Biol Phys 52:1186-95. 2002
    ..Therefore, we tried to define their incidence in such patients, to determine an in vitro dose-effect relationship, and to correlate these data with clinical parameters...
  101. pmc Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells
    Y Tao
    Laboratory UPRES EA27 10 Radiosensitivity of tumors and normal tissues, University Paris XI, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 97:1664-72. 2007
    ..These results demonstrate that PHA680632 in association with radiation leads to an additive effect in cancer cells, especially in the p53-deficient cells, but does not act as a radiosensitiser in vitro or in vivo...